Retinal vein occlusions

Developments in Ophthalmology

Volumn 47, Issue , 2010, Pages 111-135

  Jonas, Jost ^a   Paques, Michel ^b   Monés, Jordi ^d   Glacet Bernard, Agnès ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d Institut De La Macula I La Retina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956377644     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320076     Document Type: Article

References (176)

1. Hayreh SS: Occlusion of the central retinal vessels. Br J Ophthalmol 1965;49:626-645.
2. Hayreh SS: An experimental study of the central retinal vein occlusion. Trans Ophthalmol Soc UK 1964;84:586-595.
3. Coscas G, Dhermy P: Occlusions veineuses rétiniennes. Paris, Masson, 1978, pp 283-346.
4. Hayreh SS: Classification of central retinal vein occlusion. Ophthalmology 1983;90:458-474.
5. The Central Vein Occlusion Study. Baseline and early natural history report. Arch Ophthalmol 1993;111:1087-1095.
6. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995;102:1425-1433.
7. The Central Vein Occlusion Study Group N report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology 1995;102:1434-1444.
8. Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P: Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol 1990;228:201-217.
9. Coscas G, Gaudric A: Natural course of nonaphakic cystoid macular edema. Surv Ophthalmol 1984;28(Suppl):471-484.
10. Liebreich R: Ueber die Farbe des Augenhintergrundes. Albrecht Von Graefes Arch Ophthalmol 1855;1:333-358.
11. Klein R, Klein BE, Moss SE, Meuer SM: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-141.
12. Mitchell P, Smith W, Chang A: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996;114:1243-1247.
13. Wong TY, Larsen EK, Klein R, et al: Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005;112:540-547.
14. Liu W, Xu L, Jonas JB: Vein occlusion in Chinese subjects. Ophthalmology 2007;114:1795-1796.
15. Cheung N, Klein R, Wang JJ, et al: Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008;49:4297-4302.
16. Lim LL, Cheung N, Wang JJ, et al: Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol 2008;92:1316-1319.
17. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P: Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61-77.
18. O'Mahoney PR, Wong DT, Ray JG: Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008;126:692-699.
19. Hayreh S: Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493-519.
20. McIntosh R, Mohamed Q, Saw S, Wong T: Interventions for branch retinal vein occlusion. Ophthalmology 2006;114:835-854.
21. Mohamed Q, McIntosh R, Saw S, Wong T: Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2006;114:507-519.
22. Rogers S, McIntosh RL, Cheung N, et al: The prevalence and number of people with retinal vein occlusion: pooled data from population-based studies from the US, Europe, Australia and Asia. Ophthalmology 2010;117:313-319.e1.
23. Leenen FH, Dumais J, McInnis NH, et al: Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178:1441-1449.
24. Read JG, Gorman BK: Racial/ethnic differences in hypertension and depression among US adult women. Ethn Dis 2007;17:389-396.
25. Giles T, Aranda JMJ, Suh DC, et al: Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens 2007;9:345-354.
26. Ostchega Y, Hughes JP, Wright JD, et al: Are demographic characteristics, health care access and utilization, and comorbid conditions associated with hypertension among US adults? Am J Hypertens 2008;21:159-165.
27. Hayreh SS, Zimmerman MB, Podhajsky P: Hematological abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:180-196.
28. The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286-296.
29. Cugati S, Wang JJ, Knudtson MD, et al: Retinal vein occlusion and vascular mortality: pooled data analysis of 2 populationbased cohorts. Ophthalmology 2007;114:520-524.
30. Xu L, Liu W, Wang Y, Yang H, Jonas JB: Retinal vein occlusions and mortality. The Beijing Eye Study. Am J Ophthalmol 2007;144:972-973.
31. Girmens JF, Scheer S, Heron E, Sahel JA, Tournier-Lasserve E, Paques M: Familial central retinal vein occlusion. Eye 2008;22:308-310.
32. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-491.
33. Glacet-Bernard A, Bayani N, Chretien P, Cochard C, Lelong F, Coscas G: Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients. Arch Ophthalmol 1994;112:790-795.
34. Arsène S, Delahousse B, Regina S, Le Lez ML, Pisella PJ, Gruel Y: Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005;94:101-106.
35. Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO: Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 2004;137:459-464.
36. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C: High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:163-168.
37. Pinna A, Carru C, Solinas G, Zinellu A, Carta F: Glucose-6-phosphate dehydrogenase deficiency in retinal vein occlusion. Invest Ophthalmol Vis Sci 2007;48:2747-2752.
38. Koizumi H, Ferrara DC, Bruè C, Spaide RF: Central retinal vein occlusion casecontrol study. Am J Ophthalmol 2007;144:858-863.
39. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM: Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996;103:551-560.
40. Browning DJ: Patchy ischemic retinal whitening in acute central retinal vein occlusion. Ophthalmology 2002;109:2154-2159.
41. Paques M, Gaudric A: Perivenous macular whitening during central retinal vein occlusion. Arch Ophthalmol 2003;121:1488-1491.
42. Gutman FA: Macular edema in branch retinal vein occlusion: prognosis and management. Trans Am Acad Ophthalmol Otolaryngol 1977;83:488-495.
43. Hayreh SS, Hayreh MS: Hemi-central retinal vein occlusion. Pathogenesis, clinical features, and natural history. Arch Ophthalmol 1980;98:1600-1609.
44. Paques M, Girmens JF, Riviere E, Sahel J: Dilation of the minor arterial circle of the iris preceding rubeosis iridis during retinal vein occlusion. Am J Ophthalmol 2004;138:1083-1086.
45. Laatikainen L, Kohner EM: Fluorescein angiography and its prognostic significance in central retinal vein occlusion. Br J Ophthalmol 1976;60:411-418.
46. Catier A, Tadayoni R, Paques M, Erginay A, Haouchine B, Gaudric A, Massin P: Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005;140:200-206.
47. Ota M, Tsujikawa A, et al: Integrity of foveal photoreceptor layer in central retinal vein occlusion. Retina 2008;28:1502-1508.
48. Shroff D, Mehta DK, et al: Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study. Int Ophthalmol 2008;28:261-268.
49. Hitchings RA, Spaeth GL: Chronic retinal vein occlusion in glaucoma. Br J Ophthalmol 1976;60:694-699.
50. Jonas JB: Reproducibility of ophthalmodynamometric measurements of the central retinal artery and vein collapse pressure. Br J Ophthalmol 2003;87:577-579.
51. Jonas JB: Ophthalmodynamometric assessment of the central retinal vein collapse pressure in eyes with retinal vein stasis or occlusion. Graefes Arch Clin Exp Ophthalmol 2003;241:367-370.
52. Jonas JB: Central retinal artery and vein pressure in patients with chronic openangle glaucoma. Br J Ophthalmol 2003;87:949-951.
53. Jonas JB: Ophthalmodynamometric determination of the central retinal vessel collapse pressure correlated with systemic blood pressure. Br J Ophthalmol 2004;88:501-504.
54. Harder B, Jonas JB: Frequency of spontaneous pulsations of the central retinal vein in normal eyes. Br J Ophthalmol 2007;91:401-402.
55. Jonas JB, Harder B: Ophthalmodynamometric differences between ischemic versus non-ischemic retinal vein occlusion. Am J Ophthalmol 2007;143:112-116.
56. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES: Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefes Arch Clin Exp Ophthalmol 1990;228:281-296.
57. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
58. The Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986;104:34-41.
59. Hayreh SS, Rubenstein L, Podhajsky P: Argon laser scatter photocoagulation in treatment of branch retinal vein occlusion. A prospective clinical trial. Ophthalmologica 1993;206:1-14.
60. Arnarsson A, Stefánsson E: Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2000;41:877-879.
61. Maár N, Luksch A, Graebe A, Ergun E, Wimpissinger B, Tittl M, Vécsei P, Stur M, Schmetterer L: Effect of laser photocoagulation on the retinal vessel diameter in branch and macular vein occlusion. Arch Ophthalmol 2004;122:987-991.
62. Ohashi H, Oh H, Nishiwaki H, Nonaka A, Takagi H: Delayed absorption of macular edema accompanying serous retinal detachment after grid laser treatment in patients with branch retinal vein occlusion. Ophthalmology 2004;111:2050-2056.
63. Esrick E, Subramanian ML, Heier JS, Devaiah AK, Topping TM, Frederick AR, Morley MG: Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 2005;139:653-657.
64. Parodi MB, Spasse S, Iacono P, Di Stefano G, Canziani T, Ravalico G: Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 2006;113:2237-2242.
65. Hayreh SS: Management of central retinal vein occlusion. Ophthalmologica 2003;217:167-188.
66. Opremcak EM, Bruce RA: Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999;19:1-5.
67. Shah GK, Sharma S, Fineman MS, Federman J, Brown MM, Brown GC: Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2000;129:104-106.
68. Le Rouic JF, Bejjani RA, Rumen F, Caudron C, Bettembourg O, Renard G, Chauvaud D: Adventitial sheathotomy for decompression of recent onset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2001;239:747-751.
69. Cahill MT, Kaiser PK, Sears JE, Fekrat S: The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2003;87:1329-1332.
70. Fujii GY, de Juan E Jr, Humayun MS: Improvements after sheathotomy for branch retinal vein occlusion documented by optical coherence tomography and scanning laser ophthalmoscope. Ophthalmic Surg Lasers Imaging 2003;34:49-52.
71. Mason J 3rd, Feist R, White M Jr, Swanner J, McGwin G Jr, Emond T: Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology 2004;111:540-545.
72. Charbonnel J, Glacet-Bernard A, Korobelnik JF, Nyouma-Moune E, Pournaras CJ, Colin J, Coscas G, Soubrane G: Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 2004;242:223-228.
73. Yamaji H, Shiraga F, Tsuchida Y, Yamamoto Y, Ohtsuki H: Evaluation of arteriovenous crossing sheathotomy for branch retinal vein occlusion byfluorescein videoangiography and image analysis. Am J Ophthalmol 2004;137:834-841.
74. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S: Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2004;138:907-914.
75. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ: Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001;215:408-415.
76. García-Arumí J, Boixadera A, Martinez-Castillo V, Castillo R, Dou A, Corcostegui B: Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003;121:1385-1391.
77. Weizer JS, Stinnett SS, Fekrat S: Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol 2003;136:814-819.
78. Spaide RF, Klancnik JM Jr, Gross NE: Retinal choroidal collateral circulation after radial optic neurotomy correlated with the lessening of macular edema. Retina 2004;243:356-359.
79. Arevalo JF, Garcia RA, Wu L, et al, Pan-American Collaborative Retina Study Group: Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 2008;288:1044-1052.
80. Hayreh SS: Radial optic neurotomy for central retinal vein occlusion. Retina 2002;226:827.
81. Saika S, Tanaka T, Miyamoto T, Ohnishi Y: Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular edema associated with branch retinal vein occlusion: retinal tomography and visual outcome. Graefes Arch Clin Exp Ophthalmol 2001;239:729-732.
82. García-Arumí J, Martinez-Castillo V, Boixadera A, Blasco H, Corcostegui B: Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator. Retina 2004;24:530-540.
83. Mandelcorn MS, Nrusimhadevara RK: Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina 2004;24:348-355.
84. Radetzky S, Walter P, Fauser S, Koizumi K, Kirchhof B, Joussen AM: Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol 2004;242:273-278.
85. Nkeme J, Glacet-Bernard A, Gnikpingo K, Zourdani A, Mimoun G, Mahiddine H, Gkoritsa A, Tchamo A, Coscas G, Soubrane G: Surgical treatment of persistent macular edema in retinal vein occlusion. J Fr Ophthalmol 2006;29:808-814.
86. Kumagai K, Furukawa M, Ogino N, Uemura A, Larson E: Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina 2007;27:49-54.
87. Kumagai K, Furukawa M, Ogino N, Larson E, Uemura A: Long-term visual outcomes after vitrectomy for macular edema with foveal hemorrhage in branch retinal vein occlusion. Retina 2007;27:584-588.
88. Berker N, Batman C: Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 2008;86:245-252.
89. Oh IK, Kim S, Oh J, Huh K: Long-term visual outcome of arteriovenous adventitial sheathotomy on branch retinal vein occlusion induced macular edema. Korean J Ophthalmol 2008;22:1-5.
90. Arai M, Yamamoto S, Mitamura Y, Sato E, Sugawara T, Mizunoya S: Efficacy of vitrectomy and internal limiting membrane removal for macular edema associated with branch retinal vein occlusion. Ophthalmologica 2009;223:172-176.
91. DeCroos FC, Shuler RK Jr, Stinnett S, Fekrat S: Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:627-633.e1.
92. Lu N, Wang NL, Wang GL, Li XW, Wang Y: Vitreous surgery with direct central retinal artery massage for central retinal artery occlusion. Eye 2009;23:867-872.
93. Uemura A, Yamamoto S, Sato E, Sugawara T, Mitamura Y, Mizunoya S: Vitrectomy alone versus vitrectomy with simultaneous intravitreal injection of triamcinolone for macular edema associated with branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2009;40:6-12.
94. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99:753-759.
95. Stefánsson E: Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.
96. Weiss JN: Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol 1998;126:142-144.
97. Weiss JN, Bynoe LA: Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001;108:2249-2257.
98. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E: Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247-248.
99. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide as treatment of macular oedema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:782-783.
100. Park CH, Jaffe GJ, Fekrat S: Intravitreal triamcinolone acetonide in eyes with cystoidmacular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419-425.
101. Wingate RJ, Beaumont PE: Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999;27:431-432.
102. Bakri SJ, Beer PM: The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390.
103. Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW: Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-273.
104. Jonas JB, Kreissig I, Degenring RF: Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-1664.
105. Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-27.
106. Jonas JB, Bleyl U: Morphallaxia-like ocular histology after intravitreal triamcinolone acetonide. Br J Ophthalmol 2004;88:839-840.
107. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-711.
108. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr: Treatment with intravitreal steroid reduces bloodretinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110:1155-1159.
109. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL: The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
110. Penfold PL, Wong JG, Gyory J, Billson FA: Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-192.
111. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM: Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125-3130.
112. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:782-783.
113. Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN: Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004;122:1137-1140.
114. Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, Gangnon RE, Puliafito CA: Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-1136.
115. Jonas JB, Degenring R, Kamppeter B, Kreissig I, Akkoyun I: Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-160.
116. Karacorlu M, Ozdemir H, Karacorlu S: Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. Retina 2004;24:324-327.
117. Karacorlu M, Ozdemir H, Karacorlu SA: Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina 2005;25:856-860.
118. Cekiç O, Chang S, Tseng JJ, Barile GR, Weissman H, Del Priore LV, Schiff WM, Weiss M, Klancnik JM Jr: Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005;25:846-850.
119. Cekiç O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H, Schiff WM, Ober MD: Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-855.
120. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF: Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71.
121. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 2005;15:751-758.
122. Jonas JB, Kreissig I, Degenring R: Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
123. Lee H, Shah GK: Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005;25:551-555.
124. Chen SD, Sundaram V, Lochhead J, Patel CK: Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-883.
125. Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR, Ai E: Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006;26:896-901.
126. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895.
127. Jonas JB: Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006;38:218-245.
128. Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S: Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2006;244:1601-1606.
129. Bhavsar AR, Ip MS, Glassman AR, DRCRnet and the SCORE Study Groups: The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-456.
130. Hirano Y, Sakurai E, Yoshida M, Ogura Y: Comparative study on efficacy of a combination therapy of triamcinolone acetonide administration with and without vitrectomy for macular edema associated with branch retinal vein occlusion. Ophthalmic Res 2007;39:207-212.
131. Jonas JB, Rensch F: Decreased retinal vein diameter after intravitreal triamcinolone for retinal vein occlusions. Br J Ophthalmol 2007;91:1711-1712.
132. Karacorlu M, Karacorlu SA, Ozdemir H, Senturk F: Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion. Retina 2007;27:1026-1030.
133. Pathai S: Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2007;21:255-256.
134. Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, Kapran Z, Yilmaz OF: Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28:465-472.
135. Chung EJ, Lee H, Koh HJ: Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:967-974.
136. Park SP, Ahn JK: Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. Clin Experiment Ophthalmol 2008;36:831-835.
137. Parodi MB, Iacono P, Ravalico G: Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol 2008;92:1046-1050.
138. Patel PJ, Zaheer I, Karia N: Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye 2008;22:60-64.
139. Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H: Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1671-1676.
140. Roth DB, Cukras C, Radhakrishnan R, Feuer WJ, Yarian DL, Green SN, Wheatley HM, Prenner J: Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging 2008;39:446-454.
141. Cheng KC, Wu WC, Lin CJ: Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan. Eye 2009;23:849-857.
142. Gewaily D, Greenberg PB: Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2009;1:CD007324.
143. McAllister IL, Vijayasekaran S, Chen SD, Yu DY: Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009;147:838-846.
144. Scott IU, Ip MS, Van Veldhuisen PC, et al, SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-1128.
145. Wang L, Song H: Effects of repeated injection of intravitreal triamcinolone on macular oedema in central retinal vein occlusion. Acta Ophthalmol 2009;87:285-289.
146. Wu WC, Cheng KC, Wu HJ: Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 2009;23:2215-2222.
147. Scott IU, Van Veldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, SCORE Study Investigator Group: SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 2009;116:504-512.
148. Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez V, SCORE Study Investigator Group: SCORE Study Report 2: interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology 2009;116:756-761.
149. Ip MS, Scott IU, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
150. Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
151. Iturralde D, Spaide RF, Meyrele CB, et al: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
152. Jaissle GB, Ziemssen F, Petermeier K, et al: Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefässverschlü ssen. Ophthalmologe 2006;103:471-475.
153. Rosenfeld PJ, Fung AE, Pulifito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2006;36:336-339.
154. Spandau UH, Ihloff AK, Jonas JB: Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol 2006;84:555-556.
155. Costa RA, Jorge R, Calucci D, et al: Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
156. Matsumoto Y, Freund KB, Peiretti E, et al: Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431.
157. Rabena MD, Pieramici DJ, Castellarin AA, et al: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-425.
158. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-799.
159. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL: Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115:e47-e54.
160. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
161. Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM, Pegaptanib in Central Retinal Vein Occlusion Study Group: Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009;127:374-380.
162. Hansen LL, Wiek J, Schade M, Müller-Stolzenburg N, Wiederholt M: Effect and compatibility of isovolaemic haemodilution in the treatment of ischaemic and non-ischaemic central retinal vein occlusion. Ophthalmologica 1989;199:90-99.
163. Hansen LL, Wiek J, Wiederholt M: A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989;73:895-899.
164. Wolf S, Arend O, Bertram B, Remky A, Schulte K, Wald KJ, Reim M: Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol 1994;232:33-39.
165. Hattenbach LO, Wellermann G, Steinkamp GW, Scharrer I, Koch FH, Ohrloff C: Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. Ophthalmologica 1999;2136:360-366.
166. Glacet-Bernard A, Zourdani A, et al: Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2001;239:909-914.
167. McIntosh RL, Mohamed Q, Saw SM, Wong TY: Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-854.
168. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317.
169. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group: Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;1476:1048-1054.
170. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ: Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 2008;146:285-291.
171. Otani A, Dorrell MI, Kinder K, Otero FJ, Schimmel P, Friedlander M: Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest 2004;114:765-774.
172. Harris JR, Brown GA, Jorgensen M, Kaushal S, Ellis EA, Grant MB, Scott EW: Bone marrow-derived cells home to and regenerate retinal pigment epithelium after injury. Invest Ophthalmol Vis Sci 2006;47:2108-2113.
173. Smith LE: Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa. J Clin Invest 2006;114:755-757.
174. Jonas JB, Witzens-Harig M, Arseniev L, Ho AD: Intravitreal autologous bone marrow derived mononuclear cell transplantation. A feasibility report. Acta Ophthalmol 2008;86:225-226.
175. Jonas JB, Witzens-Harig M, Arseniev L, Ho AD: Intravitreal autologous bonemarrowderived mononuclear cell transplantation. Acta Ophthalmol 2009, E-pub ahead of print.
176. Ma K, Xu L, Zhang H, Zhang S, Pu M, Jonas JB: Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. Am J Ophthalmol 2009;147:326-331.